Table 1 Trials registered to NCT for repurposed drugs, of which ongoing and suspended or withdrawn. Percentages are of all registered trials
From: Missing clinical trial data: the evidence gap in primary data for potential COVID-19 drugs
Generic name | Total registered | Ongoing | Suspended/withdrawn | Completed |
|---|---|---|---|---|
Pirfenidone | 86 | 30 (34.9%) | 2 (2.3%) | 54 (62.8%) |
Hydroxychloroquine sulfate | 233 | 74 (31.8%) | 5 (2.1%) | 154 (66.1%) |
Azithromycin | 457 | 98 (21.4%) | 16 (3.5%) | 343 (75.1%) |
Favipiravir | 12 | 3 (25.0%) | 0 (0.0%) | 9 (75.0%) |
Oseltamivir | 127 | 18 (14.2%) | 8 (6.3%) | 101 (79.5%) |
Sarilumab | 37 | 19 (51.4%) | 0 (0.0%) | 18 (48.6%) |
Tocilizumab (atlizumab) | 360 | 84 (23.3%) | 9 (2.5%) | 267 (74.2%) |
Remdesivir | 12 | 11 (91.7%) | 0 (0.0%) | 1 (8.3) |
Leflunomide | 25 | 4 (16.0%) | 1 (4.0%) | 20 (80.0%) |
Interferon-alpha | 1161 | 71 (6.1%) | 41 (3.5%) | 1049 (90.4%) |
Lopinavir/ritonavir | 1015 | 66 (6.5%) | 22 (2.2%) | 927 (91.3%) |
Darunavir/ritonavir | 246 | 26 (10.6%) | 4 (1.6%) | 216 (87.8%) |
Baloxavir marboxil | 9 | 4 (44.4%) | 0 (0.0%) | 5 (55.6%) |
Umifenovir | 10 | 8 (80.0%) | 0 (0.0%) | 2 (20.0%) |
Interferon-beta | 343 | 43 (12.5%) | 15 (4.4%) | 285 (83.1%) |
Sofosbuvir | 261 | 75 (28.7%) | 10 (3.8%) | 176 (67.4%) |
Nitazoxanide | 57 | 8 (14.0%) | 1 (1.8%) | 48 (84.2%) |
APN01 (ACE2 analogue) | 1 | 0 (0.0%) | 0 (0.0%) | 1 (100.0%) |
Ivermectin | 101 | 19 (18.8%) | 4 (4.0%) | 78 (77.2%) |
Totals | 4553 | 661 (14.5%) | 138 (3.0%) | 3754 (82.5%) |